GlycoSeLect
Developing life-changing biotherapeutic medicines faster and cheaper
Accelerating the delivery of biotherapeutics to market
Dublin City University spinout, GlycoSeLect, partnered with CPI to develop, demonstrate and de-risk their innovative analytical technology platform.
GlycoSeLect is an early-stage biotechnology company that develops innovative solutions for the analysis, characterisation and purification of pharmaceutical products through their RPL technology.
![](https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/biotherapeutics-ambr-two-image.jpg?w=1920&h=1080&q=60&fm=jpg&fit=crop&dm=1559218286&s=26295e361f2db1a0bc15d5f5c856f5e8 1920w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/biotherapeutics-ambr-two-image.jpg?w=1120&h=630&q=60&fm=jpg&fit=crop&dm=1559218286&s=56a063a71dd210cd014ccb32fece8211 1120w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/biotherapeutics-ambr-two-image.jpg?w=800&h=450&q=60&fm=jpg&fit=crop&dm=1559218286&s=1c954a7174831c826b20b0bcad57b300 800w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/biotherapeutics-ambr-two-image.jpg?w=1600&h=900&q=45&fm=jpg&fit=crop&dm=1559218286&s=a080960e45f681bdb239163c811dd236 1600w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/biotherapeutics-ambr-two-image.jpg?w=480&h=270&q=60&fm=jpg&fit=crop&dm=1559218286&s=31c18e033b81ffe00e5c47b50bf723f1 480w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/biotherapeutics-ambr-two-image.jpg?w=960&h=540&q=45&fm=jpg&fit=crop&dm=1559218286&s=162db8d972970ed4b2a95b69335f7e15 960w)
“ The expertise and support of our CPI colleagues was crucial in the successful completion of this technically challenging project. ”
![Robert Dunne Robert Dunne](https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/Robert-Dunne.jpg?w=100&h=100&q=60&fm=jpg&fit=crop&dm=1632736821&s=2843d96407753854d2a63fc0bfa2bf72)
Achievements
Inputs
- Technical knowledge and expertise
- Access to state-of-the-art equipment
- Signposting
- Consultancy
Outputs
- TRL progression (3 – 9)
- Proven proof of concept
- Enhanced product and process
- Upskilled workforce
- Further R&D projects
Outcomes
- Enhanced service offering
- Job creation in the UK & Ireland
- Improved product to market
- Demonstrable >80% cost reduction
- Increase speed of analysis >90%
![](https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/pharma-processing-vials.jpg?w=1920&h=1080&q=60&fm=jpg&fit=crop&dm=1620913114&s=5d195b9177efd1d16086c3e9f5f03d51 1920w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/pharma-processing-vials.jpg?w=1120&h=630&q=60&fm=jpg&fit=crop&dm=1620913114&s=66bb15456652304e3fa44f0b907ac362 1120w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/pharma-processing-vials.jpg?w=800&h=450&q=60&fm=jpg&fit=crop&dm=1620913114&s=4ac26201056508d8b5356439b5355196 800w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/pharma-processing-vials.jpg?w=1600&h=900&q=45&fm=jpg&fit=crop&dm=1620913114&s=5955dc765f243158a195579ba0c062e6 1600w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/pharma-processing-vials.jpg?w=480&h=270&q=60&fm=jpg&fit=crop&dm=1620913114&s=255944fbc25ce3820d4ffd64b2faf91c 480w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/pharma-processing-vials.jpg?w=960&h=540&q=45&fm=jpg&fit=crop&dm=1620913114&s=b326268748262e01c3c7883f27288966 960w)
The challenge
Biotherapeutic medicines have been shown to be highly effective in the treatment of a multitude of autoimmune diseases and cancers. Characterising the glycan profile of the biotherapeutic is not only key to product quality but also critical in delivering safe and effective medicines to patients.
However, the development and manufacture of these potentially life-changing treatments carries a high risk of failure, is technically challenging and expensive.
With more than two-thirds of biotherapeutics existing in a glycosylated form, it is important that the glycan profile is monitored throughout product development and manufacture to ensure statutory requirements are in place to reduce clinical trial risks.
CPI’s role in the project was to demonstrate proof of concept of the technology for purified and in-process analysis. Further tests were conducted to demonstrate the linearity, repeatability and robustness of the technology methodology.
How CPI helped
In 2016 GlycoSeLect moved into the South Tees Bio-incubator; a strategic partnership between South Tees Hospitals’ NHS Trust and CPI. The South Tees Bio-Incubator space allows early-stage biotechnology and life sciences companies to become established by providing access to expert advice and shared laboratory space to facilitate product development and realise commercial success.
CPI supported GlycoSeLect through two collaborative R&D products with Glythera, ForteBio-Molecular Devices and Allergan Biologics Ltd to address the need for new analytical approaches to satisfy the growing biotherapeutics market.
The first collaborative project led by Glythera centred around their Permacarb™ technology, which is used to stabilise the glycan moieties (a distinct part of a large molecule) of a biotherapeutic drug with the aim of reducing patient dosing cycles. GlycoSeLect and CPI partnered with Glythera to develop a lectin-based assay to complement Glythera’s Permacarb™ technology.
The second follow on project enabled CPI and GlycoSeLect to develop a novel glycan analysis tool utilising biosensor technology to create a platform with the capability to reduce costs and accelerate product development pipelines. This resulted in a market evaluation assessment for the analytical technology and potential new markets in which the technology could provide significant benefits.
Following this work, the technology can now be performed up to 92% faster with a cost reduction of over 85%. The technology is suitable for both final and in-process sample analysis thereby overcoming limitations on existing glycoanalytical offerings and offers additional value as a Quality Control Assay (CQA) due to its ability to conduct real-time analysis through the entire product development pipeline to manufacture.
The products have already generated significant industry interest, leading to orders being placed by a UK PLC and University whilst the work was still underway.
CPI’s contribution to the project led to significant cost savings in development and manufacturing timelines helping to accelerate delivery of biotherapeutics to market. The technology can now be performed faster, cheaper and with a higher quality output than existing technologies, enabling GlycoSeLect to expand their commercial offerings and ultimately leading to high value job creation within the UK.
Related
Technologies
Markets
![](https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/biotherapeutics-analytical-two-image.jpg?w=1920&h=1080&q=60&fm=jpg&fit=crop&dm=1559218265&s=069e605533c26faa2e8e4a78192fb4ec 1920w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/biotherapeutics-analytical-two-image.jpg?w=1120&h=630&q=60&fm=jpg&fit=crop&dm=1559218265&s=579a767063aa1530a540e0be80dffa8b 1120w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/biotherapeutics-analytical-two-image.jpg?w=800&h=450&q=60&fm=jpg&fit=crop&dm=1559218265&s=17e5a40e49798060259c38a89b20cc80 800w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/biotherapeutics-analytical-two-image.jpg?w=1600&h=900&q=45&fm=jpg&fit=crop&dm=1559218265&s=7412247a655e3f6ed00ea5e450cf8d25 1600w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/biotherapeutics-analytical-two-image.jpg?w=480&h=270&q=60&fm=jpg&fit=crop&dm=1559218265&s=a0309c4e4bb4df4e34c5b5fcfafb4778 480w, https://optimise2.assets-servd.host/smart-hoopoe/production/content/images/biotherapeutics-analytical-two-image.jpg?w=960&h=540&q=45&fm=jpg&fit=crop&dm=1559218265&s=f53f90d17e7c520955ca0377e607683a 960w)